Loading…
Altimmune, Inc. is projected to rise to $3.84 by 2027, a +35% move from its current price of $2.84. ALT is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/1/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 2 | $2.77 | $2.84 | $2.91 | +0.02% |
| Aug 3 | $2.74 | $2.84 | $2.94 | +0.05% |
| Aug 4 | $2.72 | $2.84 | $2.97 | +0.07% |
| Aug 5 | $2.70 | $2.84 | $2.99 | +0.10% |
| Aug 6 | $2.69 | $2.84 | $3.01 | +0.12% |
| Aug 7 | $2.68 | $2.84 | $3.02 | +0.15% |
| Aug 8 | $2.66 | $2.84 | $3.04 | +0.17% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.66 | $2.84 | $3.04 | +0.17% |
| Week 2 | $2.60 | $2.85 | $3.13 | +0.34% |
| Week 3 | $2.55 | $2.85 | $3.20 | +0.52% |
| Week 4 | $2.51 | $2.86 | $3.26 | +0.69% |
| Week 5 | $2.47 | $2.86 | $3.32 | +0.86% |
| Week 6 | $2.44 | $2.87 | $3.37 | +1.03% |
| Week 7 | $2.41 | $2.87 | $3.42 | +1.21% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Altimmune, Inc. is a healthcare company described as a late clinical stage biopharmaceutical company that focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease.
The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
Altimmune operates in the Healthcare category and pursues therapies aimed at serious liver-related conditions through late-stage development efforts. This positioning places its products in a high-need therapeutic area with ongoing clinical evaluation for multiple indications.
These facts place Altimmune in the biotechnology/pharmaceuticals landscape, with a focused pipeline centered on pemvidutide and liver-associated diseases, as it continues to advance its clinical program.
Altimmune, Inc. is currently trading at $2.85 per share with a market capitalization of $554.25M, and it is ranked 2911 by market cap.
The latest forecast shows a neutral start in 2026, with an average price of $2.85 and a 0% ROI, followed by a bullish trajectory in subsequent years as the average price grows and sentiment strengthens.
From 2027 onward, the forecast projects a clear upward path in the average price, reaching $15.80 by 2050, with strong annualized gains along the way. Key mid-range milestones include an average of $3.75 in 2027 and progress toward higher targets through 2030, 2040, and 2050.
A major floor 14.1% below — a decisive break under it would weaken the trend.
The nearest floor, 4.9% below — buyers have tended to step in here.
The nearest ceiling, 11.3% above — a clean break opens room to run.
A major ceiling 25.4% above — clearing it would confirm fresh momentum.
Key ALT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ALT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.94 | Sell | $2.90 | Sell |
| MA 10 | $2.87 | Sell | $2.90 | Sell |
| MA 20 | $2.94 | Sell | $2.91 | Sell |
| MA 50 | $2.89 | Sell | $2.95 | Sell |
| MA 100 | $3.04 | Sell | $3.17 | Sell |
| MA 200 | $3.76 | Sell | $3.62 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 46.02 | Neutral |
| Stoch RSI (14) | 36.20 | Neutral |
| CCI (20) | -71.06 | Neutral |
| Williams %R (14) | -68.18 | Info |
| MACD (12,26,9) | -0.00 | Sell |
| ROC (12) | -4.70 | Sell |
| Bollinger %B (20,2) | 0.27 | Neutral |
| Stochastic %K (14) | 31.82 | Neutral |
| TRIX (15) | -0.00 | Sell |
| Awesome (5,34) | 0.03 | Buy |
| Ultimate (7,14,28) | 48.80 | Neutral |
| Momentum (10) | -0.03 | Sell |
| Aroon Osc (25) | -60.00 | Sell |
| Hull MA (9) | 2.96 | Sell |
| ADX (14) | 11.37 | Neutral |
| ATR (14) | 0.07 | Info |
The 30-day technical picture is Bearish. RSI(14) is 40, indicating modest downside momentum.
The moving averages show the short-term trend below the longer-term trend, with SMA50 at $2.91 and SMA200 at $3.82, suggesting continued pressure near the near-term resistance level.
In the near term, price action has a defined range between $2.42 and $3.35 over the last 30 days, with a known support at $2.59 and a resistance at $3.16. Annualized volatility sits at 50%, underscoring elevated price movement potential within the current environment.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.59 | $2.84 | $3.82 | 0% | Neutral | |
| $3.09 | $3.84 | $5.03 | +35% | Bullish | |
| $3.31 | $4.23 | $5.74 | +49% | Bullish | |
| $3.32 | $4.33 | $6.03 | +52% | Bullish | |
| $3.56 | $4.72 | $6.74 | +66% | Bullish | |
| $3.51 | $4.74 | $6.90 | +67% | Bullish | |
| $3.70 | $5.07 | $7.51 | +79% | Bullish | |
| $4.44 | $6.17 | $9.30 | +117% | Bullish | |
| $4.72 | $6.66 | $10.18 | +134% | Bullish | |
| $5.10 | $7.29 | $11.30 | +157% | Bullish | |
| $6.62 | $10.05 | $16.50 | +254% | Bullish | |
| $10.01 | $16.82 | $30.05 | +492% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $2.59 | $2.84 | $3.41 | +0.00% |
| September 2026 | $2.48 | $2.92 | $3.54 | +2.94% |
| October 2026 | $2.45 | $2.90 | $3.55 | -0.66% |
| November 2026 | $2.44 | $2.91 | $3.59 | +0.32% |
| December 2026 | $2.56 | $3.07 | $3.82 | +5.43% |
Click any year to see its month-by-month ALT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Altimmune, Inc.'s 2026 outlook centres on $2.84, within a $2.59 to $3.82 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, ALT could reach as high as $5.03, with a base case around $3.84 and support toward $3.09 — roughly +35% from $2.84. Buyers look set to stay in control over this stretch.
Expect ALT to range from $3.31 to $5.74 through 2028. The $4.23 average target implies a +49% move from current prices. That is up +10% on the projected 2027 average. Momentum favours further upside here.
The ALT price prediction for 2029 points to an average of $4.33 (low $3.32, high $6.03) — a potential gain of +52% on today's $2.84. Buyers look set to stay in control over this stretch.
In 2030, ALT is projected to trade between $3.56 and $6.74, averaging $4.72 — a potential gain of +66% from today's $2.84. That is up +9% on the projected 2029 average. Momentum favours further upside here.
Altimmune, Inc.'s 2031 outlook centres on $4.74, within a $3.51 to $6.90 range. That is up 0% on the projected 2030 average. That marks a +67% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, ALT could reach as high as $7.51, with a base case around $5.07 and support toward $3.70 — roughly +79% from $2.84. Momentum favours further upside here.
Expect ALT to range from $4.44 to $9.30 through 2033. The $6.17 average target implies a +117% move from current prices. That is up +22% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The ALT price prediction for 2034 points to an average of $6.66 (low $4.72, high $10.18) — a potential gain of +134% on today's $2.84. Momentum favours further upside here.
In 2035, ALT is projected to trade between $5.10 and $11.30, averaging $7.29 — a potential gain of +157% from today's $2.84. That is up +9% on the projected 2034 average. Buyers look set to stay in control over this stretch.
Altimmune, Inc.'s 2040 outlook centres on $10.05, within a $6.62 to $16.50 range. That is up +38% on the projected 2035 average. That marks a +254% change versus current levels. Momentum favours further upside here.
By 2050, ALT could reach as high as $30.05, with a base case around $16.82 and support toward $10.01 — roughly +492% from $2.84. Buyers look set to stay in control over this stretch.
Investing $1,000 in ALT today (≈ 352.112676 ALT) could be worth
$5,920.85
+$4,920.85 (+492%) by 2050 · US Dollar
Based on the average projected ALT price of $16.82 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ALTwould be worth at today's price.
$1,000 invested in ALT on Jul 31, 2025 (≈ 271.002706 ALT) would be worth
$769.65
-$230.35 (-23.0%) today · 0.77× · US Dollar
Based on a ALT entry price of $3.69 vs. today's $2.84.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.77 | $1,025.27 | +2.5% |
| 1 month ago | $3.15 | $901.59 | -9.8% |
| 3 months ago | $2.82 | $1,007.09 | +0.7% |
| 6 months ago | $5.55 | $511.71 | -48.8% |
| 1 year ago | $3.69 | $769.65 | -23.0% |
| All time (5.0y) ago | $9.24 | $307.36 | -69.3% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ALT forecast.
Our base-case forecast reaches $5.70 around 2033.
Implied market cap at $5.70: $1.11B
The multi-year forecast paints a bullish longer-term path, with notable milestones in the Avg and ROI figures.
In 2030, the average price is forecast at $4.54 with a 59.4% ROI and bullish sentiment. Earlier years show continued upside: 2027 avg $3.75 (ROI 31.5%), 2028 avg $4.18 (ROI 46.6%), 2029 avg $4.28 (ROI 50.2%), and 2031–2032 continuing higher (2031 avg $4.63, ROI 62.3%; 2032 avg $4.89, ROI 71.5%). By 2033 the avg is $5.83 (ROI 104.7%), and the path remains bullish through 2035 (avg $6.95, ROI 143.8%).
The forecast accelerates through 2040 with an avg of $9.42 and a 230.4% ROI, and by 2050 the avg reaches $15.80 with a 454.4% ROI, signaling a strong long-term upside if the projections materialize. These figures reflect a bullish sentiment across the long horizon, but they are estimates and not guarantees.
Tap a question to reveal the answer.
2030 forecast: min $3.43, avg $4.54, max $6.48; ROI 59.4%; sentiment BULLISH.
Forecasts show a bullish trajectory from 2027 onward, with the average price rising to $15.80 by 2050 and ROI reaching 454.4%. These are estimates and not guarantees, and risks remain.
Yes. The forecast includes a 2035 max of $10.75 and a 2040 max of $15.42, with a 2050 max of $28.15, indicating potential to reach and exceed $10 in the mid- to late-2030s.
2026 forecast: min $2.59, avg $2.85, max $3.90; ROI 0; sentiment NEUTRAL.
Current price is $2.85 per share and market capitalization is $554.25M; rank 2911.
Altimmune, Inc. Community Discussion
0Share your Altimmune, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.